article Open AccessTop 1% cited

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

New England Journal of Medicine · 2005 · Vol. 352(10) · pp. 997–1003

Monika E. Hegi✉(University Hospital of Lausanne)Annie‐Claire DiserensThierry GorliaMarie‐France HamouNicolas de Tribolet(University Hospital of Geneva)Michael Weller(University of Tübingen)Johan M. Kros(Rotterdam University of Applied Sciences)Johannes A. Hainfellner(Medical University of Vienna)Warren Mason(Princess Margaret Hospital)Luigi Mariani(University Hospital of Bern)Jacoline E. C. Bromberg(University Medical Center Utrecht)Peter Hau(University of Regensburg)R.O. MirimanoffJ. Gregory Cairncross(University of Calgary)Robert C. JanzerRoger Stupp

View via DOI Full-text PDF

Abstract

Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

Glioma Diagnosis and Treatment Epigenetics and DNA Methylation Histone Deacetylase Inhibitors ResearchTemozolomideMedicineO-6-methylguanine-DNA methyltransferaseMethyltransferaseHazard ratioOncologyMethylationConfidence intervalDNA methylationInternal medicine

MeSH terms

TemozolomideBrain NeoplasmsDacarbazineGlioblastomaHumansPromoter Regions, GeneticSurvival AnalysisRandomized Controlled Trials as TopicPolymerase Chain ReactionChemotherapy, AdjuvantDisease-Free SurvivalAntineoplastic Agents, AlkylatingDNA MethylationO(6)-Methylguanine-DNA MethyltransferaseGene Silencing

Citations

7,163

FWCI

84.37

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Management of glioblastoma: State of the art and future directions